Viewing Study NCT04895020


Ignite Creation Date: 2025-12-25 @ 4:07 AM
Ignite Modification Date: 2026-02-11 @ 8:08 AM
Study NCT ID: NCT04895020
Status: RECRUITING
Last Update Posted: 2024-04-17
First Post: 2021-05-17
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module